What Recent Texas Pharmacy Board Decisions Mean for Compounding Pharmacies in 2026

The 2026 Enforcement Shift

Section summaryEarlier compounding enforcement was facility-focused: physical space, hoods, garbing rooms. Recent cases are documentation-focused: the records the pharmacy keeps about what it did, when, with which inputs, and verified by whom.

If you compare a 2022 Board order against compounding pharmacy to one issued in early 2026, the change is visible in the factual allegations. The earlier orders read like inspection reports: this hood, this room, this sterilization indicator, this temperature log. The newer orders read like document audits: this BUD justification was not supported by stability data, this environmental sampling result was not addressed in a deviation report, this technician's annual competency assessment was not on file at the time of the inspection.

The shift is partly driven by the maturation of Chapter 565 enforcement and the Board's rulemaking around compounding standards. It is also driven by the broader regulatory environment after high-profile compounding incidents in recent years made every compounding pharmacy a more closely-watched operation. Whatever the cause, the practical effect is that the records are the case. Pharmacies that previously survived inspections on the strength of clean facilities are now generating complaint files on the basis of paperwork.

For defense counsel, this changes how a TSBP case is workable. Earlier facility cases often hinged on a single observable condition — was the hood certified, was the door interlock functional. Documentation cases involve aggregated, system-level allegations. The defense response has to address the documentation system as a whole, not just individual line items. The general framework is laid out in our Texas Pharmacy Board discipline guide; the 2026 layer is everything that follows.

Sterile Compounding (USP 797)

Section summarySterile-compounding cases now routinely allege deficiencies in environmental monitoring, media fill records, beyond-use date justification, and personnel competency files. Each is its own evidentiary lane.

The Board's sterile-compounding rules adopt USP Chapter 797 as the operational standard for pharmacies preparing compounded sterile preparations. Inspectors evaluating sterile-compounding operations now look at several documentation domains as separate lines of inquiry.

Environmental monitoring is one of the most-cited categories. Pharmacies must maintain viable and non-viable air sampling records, surface sampling records, and trend analysis. Allegations in 2026 often go beyond "monitoring was not performed" — they identify specific results that exceeded action levels and were not addressed in a documented corrective action.

Media fill testing for personnel competency is another sharp inquiry. The Board's allegations sometimes identify by name which compounding personnel had no recent media fill on file at the time of the inspection. Beyond-use dating is now allegations-by-product: this particular preparation was assigned a 30-day BUD without stability data supporting that interval, contrary to USP 797's default categories.

The defense response to a sterile-compounding case has to engage at the same granularity. Aggregate compliance statements are not enough. The framework for negotiating these matters at ISC or contesting them at SOAH is the same as for any TSBP case (see our SOAH Hearing Preparation guide), but the evidentiary build-out is heavier.

Non-Sterile Compounding (USP 795)

Section summaryNon-sterile compounding has historically been lower-stakes enforcement territory. Recent cases show that is changing, with BUD documentation and ingredient sourcing emerging as the principal pressure points.

USP Chapter 795 governs non-sterile compounding, and for most of the last decade it generated comparatively few Board cases. That has shifted. The 2026 trend includes formal complaints against non-sterile-only pharmacies — pharmacies that previously assumed they were outside the heavy enforcement zone.

Beyond-use dating is the central allegation category. USP 795 provides default BUD categories for non-sterile preparations, and assigning a longer BUD requires documented justification supported by stability information for the specific formulation. Allegations now identify particular preparations with assigned BUDs and ask, in effect, where the stability data is. If the file says "stable for 90 days" without supporting documentation, the assignment itself becomes the violation.

Ingredient sourcing is the other emerging pressure point. The Board has shown increased interest in active pharmaceutical ingredient sourcing — certificates of analysis, supplier qualification, and the audit trail for compounded preparations made from bulk APIs. For pharmacies compounding from FDA-approved manufactured products this is less relevant; for pharmacies sourcing bulk APIs, the documentation expectations are now explicit.

A pharmacy facing this category of complaint should triage the systemic exposure before drafting any response. Our License Risk Triage tool helps surface the practice-wide patterns that a single-complaint response can otherwise miss. Owners and pharmacists-in-charge should also be thinking about regulatory exposure in tandem with any criminal-law exposure that ingredient or controlled-substance issues might trigger — the Texas Statute of Limitations checker can clarify timelines on parallel risks.

Hazardous Drugs (USP 800)

Section summaryHazardous-drug handling under USP 800 has emerged as a distinct enforcement track in 2026, particularly for pharmacies preparing oncology compounds. Containment, personal protective equipment, and assessment of risk documentation are the focus.

USP Chapter 800 sets standards for handling hazardous drugs in healthcare settings. Pharmacies preparing oncology compounds, certain hormone therapies, or other listed hazardous drugs are subject to its containment, ventilation, PPE, and decontamination requirements. The Board has incorporated USP 800 into its rule structure, and inspections now include USP 800 as a distinct review category.

Allegations under this rubric in 2026 have included inadequate containment ventilated enclosures, missing assessments of risk documentation for facilities relying on alternative containment strategies, and gaps in personal protective equipment training records. For a pharmacy that primarily focused on USP 797 compliance and treated USP 800 as a subset, this is a meaningful adjustment.

The defense angle is that USP 800 contains explicit pathways for risk-based assessment when full containment is not feasible — but those pathways require documentation. A pharmacy that has been operating under an informal risk-assessment approach without written documentation is in the same evidentiary position as a pharmacy that has no assessment at all.

The Documentation Standard

Section summaryThe unifying theme across sterile, non-sterile, and hazardous-drug enforcement in 2026 is documentation. The Board is not asking whether good practice happened; it is asking for the contemporaneous records that prove it.

Across the three compounding domains, the pattern is consistent: the Board's enforcement posture treats undocumented practice as non-compliant practice. This is not new as a regulatory principle — quality systems regulation has worked this way for a long time — but the rigor of its application to Texas compounding pharmacies in 2026 is new.

For pharmacy owners and pharmacists-in-charge, the practical implication is that compliance posture is now a documentation question as much as it is an operational one. A pharmacy that runs a clean operation but documents inconsistently is now at meaningful enforcement risk. A pharmacy that documents thoroughly even where operations have minor gaps is in a stronger defensive position because the gaps can be addressed in dialogue with the Board rather than charged in a formal complaint. The broader regulatory map for pharmacists, owners, and PICs facing this environment is laid out in our Texas Professional License Defense Guide.

For any pharmacy currently facing an inspection finding or an opened complaint, the same documentation principles guide the response. The written submission should engage the documentation evidence on its own terms — explaining what records exist, what records have been added or updated, and what systems are now in place. A defensive narrative that does not engage the records will not resolve a records-driven complaint. And before accepting any Agreed Order, the licensee should evaluate the downstream NPDB and NABP Clearinghouse reporting consequences — those are governed by the same considerations covered in our National Practitioner Data Bank reporting guide.

Frequently Asked Questions

Next Steps

If you are facing a situation described here, consult counsel promptly. Many issues in this area run on strict deadlines.

• Call (972) 370-5060
• Email info@landllawgroup.com